-
Kenya's economy faces climate change risks: World Bank
-
Hollywood powerhouses bring AI fight to Europe
-
Rubio says US will not accept Iranian tolls on Hormuz
-
UN to begin evacuating stranded Mideast sailors after US-Iran talks
-
French farmers suffer arid crops, heat-stricken animals
-
Scorching heat shuts Paris landmarks early as France swelters
-
Hundreds of schools close as UK braces for record-breaking heatwave
-
ACTIVIST SHAREHOLDER FILES SCHEDULE 13D IN EQUUS TOTAL RETURN, INC.
-
Europe: the world's fastest-warming continent
-
Europe heatwave closes schools, threatens health
-
India monsoon sweeps north but brings less rain than usual
-
Germany eyes longer working lives in pension reform plan
-
Heineken names new CEO after predecessor's shock departure
-
Schools plan to close as UK braces for record-breaking heatwave
-
More records set to fall as deadly Europe heatwave drags on
-
Iran says to oversee Hormuz as Swiss talks conclude
-
Indian startup head appointed as new WhatsApp boss
-
Shortages ease in Bolivia as protest roadblocks dismantled
-
France-Iraq World Cup game suspended due to severe weather alert
-
Maduro ouster put Venezuela on 'the right path': interim leader
-
Latest developments in Europe's heatwave
-
IMF director says Iran war fallout creating 'difficult moment' for Africa
-
Wikipedia won't let AI edit articles, cofounder says
-
Dangerous 'heat stress' has surged worldwide, study shows
-
Interstellar comet likely far older than Solar System: astronomers
-
Two children found dead in car as France faces hottest day of heatwave
-
Two children die in France as heatwave blasts Europe
-
Alan Greenspan: longtime Fed chief with a divided legacy
-
France, Germany reach deal on arms maker KNDS, paving way for IPO
-
MEXC Lists Arcium (ARX) with 70,000 USDT in Airdrop+ Rewards
-
EasyJet rejects £5 bn takeover offer from US equity firm
-
Europe scorched by latest heatwave
-
Crude prices drop after 'positive' US-Iran talks
-
European countries close schools, cancel trains as heatwave set to intensify
-
Crude prices drop, most stocks rise on 'positive' US-Iran talks
-
Trump say repairs to begin 'immediately' for Washington pool renovation
-
Legendary Cuban spy chief Ramiro Valdes dies at 94
-
Bolivia removes roadblocks after emergency decree
-
Nigerian twins Taiwo and Kehinde marry... Taiwo and Kehinde
-
France presses ahead with street music festival despite extreme heat
-
France presses ahead with street music festivals despite extreme heat
-
France presses ahead with music festivals despite extreme heat
-
Pakistan's mango exports shrink as Middle East war impacts linger
-
Britain's King Charles to reveal personal tax bill: reports
-
Bolivia declares state of emergency, deploys military to quell protests
-
Driver killed, 28 in hospital as UK train collision probed
-
'Like a fridge': France cave homes offer lucky few respite from heat
-
Hormuz ship traffic climbs after war deal: trackers
-
'There's no soul': Tony Leung weighs in on AI in filmmaking
-
French mountain lodges worry over strained water supply
Brazilian ritual root gets second life as potential anti-depressant
Long used in Indigenous Brazilian rituals, the jurema preta plant, which contains a potent psychedelic, is gaining ground as a potential treatment for depression.
At street stalls where medicinal herbs are sold, customers can buy the plant's root which contains dimethyltryptamine (DMT), a hallucinogenic substance that researchers say could be used to alleviate symptoms.
Following instructions he found on the internet, Guaracy Carvajal extracted DMT at home in 2016 from roots he bought on the street.
The 31-year-old software programmer, who had tried various treatment for chronic depression he has suffered since adolescence, said the drug makes it "feel like you've solved something in your life."
Physicist Draulio Araujo, who has conducted extensive research on the drug, said "the response is rapid. One day after treatment, (patients) already showed a significant improvement in their depression symptoms."
Yet he also warned that it "is not a magic cure" and that psychedelics "are not for everyone."
As a researcher at the Brain Institute of the Federal University of Rio Grande do Norte, Araujo and his team treated 14 people with the drug for six months.
The patients inhaled vaporized DMT, under medical supervision.
"It's common for our patients to say that something changed, that a key opened something," he said.
His patients also received psychological therapy, and some continued with conventional pharmaceutical drugs.
Neuroscientist Fernanda Palhano-Fontes, also of the Brain Institute, said "we have patients who improve significantly, others who don't improve at all."
Araujo's findings were published in the scientific journal Nature in April. In 2024, he published another study with promising results in the journal Psychedelic Medicine.
As for Carvajal, who stopped using jurema preta some time ago, he said the drug really allows a person to "start to have a lighter life."
It helped him get through a time when he was in "a state of questioning myself" about "work, day-to-day life," he said.
- Spiritual channels -
Brazil occupies a fairly prominent place in DMT research due to the substance's prominence in society, Araujo said.
While there is no ban on the cultivation or possession of jurema, which is also known as Mimosa tenuiflora, consumption of DMT is prohibited, except for religious and scientific use.
Jurema's roots are combined with other plants in a wine-like beverage that is consumed at rituals that include dancing and drums, part of Indigenous tradition in northeast Brazil where the plant grows.
"It's not hallucination," said Joyce Souza, a young woman attending a jurema ceremony in Planaltina, on the outskirts of Brasília.
"My spiritual channels become more accessible, I can communicate better with myself," Souza said.
Gathered in a house courtyard and dressed in white, the group of mostly novices waited for more seasoned practitioners to enter a trance and bring messages from ancient spirits.
Meanwhile, back in the lab, Araujo is hoping to expand his DMT research to a study of 100 patents.
"Let's say that in five years we'll have... a clear picture on when it will reach a real clinical setting," he said.
X.Cheung--CPN